自行注射PCSK9抑制剂的不完整剂量相关并发症的营销后报告:描述性研究和不成比例分析
1Levin, Papantonio, Rafferty, Proctor, Buchanan, O'Brien, Barr and Mougey, P.A., 316 South Baylen Street, Pensacola, FL, 32502, USA. rwoods@levinlaw.com.
概括
市场营销后的报告显示,自我注射的蛋白转化酶抑制剂9型 (PCSK9) 抑制剂的剂量并发症不完全. 埃沃洛库马布显示了剂量失效的信号,而阿利罗库马布则没有,表明需要进一步调查.
科学领域:
- 药物监督 药物监督 药物监督
- 心血管医学 心血管医学
- 药物输送系统 药物输送系统
背景情况:
- 埃沃洛库马布和阿利罗库马布是自我注射的PCSK9抑制剂,用于降低LDL胆固醇.
- 设备并发症可能导致这些药物的剂量不完全.
研究的目的:
- 分析市场营销后关于自注射PCSK9抑制剂剂量失败的报告.
- 为了识别与evolocumab和alirocumab相关的剂量问题的潜在信号.
主要方法:
- 美国FDA FAERS数据 (2016-Q2 2023) 的不成比例分析,将PCSK9抑制剂与其他八种自我注射药物进行比较.
- 对美国FDAMAUDE数据 (2013-2023) 的叙述性综述,用于与设备相关的事件.
- 使用"监管活动医学词典"术语识别剂量失败.
主要成果:
- 检测到埃沃洛库马布 (PRR 2.01) 的剂量失效信号,但没有发现阿利罗库马布 (PRR 0.99).
- 埃沃洛库马布显示患者使用并发症的不成比例信号 (PRR 3.44).
- 阿利罗马布显示了设备故障的不成比例信号 (PRR 2.09).
结论:
- 在市场营销后,PCSK9抑制剂的不完整剂量并发症经常被报告.
- 需要进一步的研究来了解剂量失效的发生率,机制和患者影响.
相关概念视频
Pharmacovigilance
821
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
821
Nonlinear Pharmacokinetics: Overview
352
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
352
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
120
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
120
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
646
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
646
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K


